MedTrace Logo

Predicting Immunotherapy Response and Survival of Liver Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Liver)

NCT07059936 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2025-07-22

No results posted yet for this study

Summary

CT imaging data and MR imaging data from liver cancer (hepatocellular carcinoma) patients prior to the initiation of immunotherapy (and possibly also after treatment) will be collected. The processing pipeline includes automatic tumor segmentation, radiomics feature extraction, feature selection, and construction of a classification model.

Conditions

  • Hepatocellular Carcinoma (HCC)

Sponsors & Collaborators

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-31
Primary Completion
2026-09-30
Completion
2026-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07059936 on ClinicalTrials.gov